Most investment stories stop at the return.
But that's where ours starts.
Most investment stories stop at the return, but that's where ours starts.
We’ve built a model where billion-dollar outcomes lift millions of children, patients, and entire communities.
HOW IT WORKS
We invest in pioneering companies shaping the future.
Develops and launches reusable rockets and spacecraft, including Starship, to reduce the cost of space access.
A clinical stage med-tech/neurotech company developing devices for debilitating conditions.
An Al safety and research company (PBC) building reliable, steerable Al systems like Claude.
Al company aiming to advance scientific discovery and understanding of the universe (creator of Grok).
Research company building open-weight Al models and autonomous coding agents toward open superintelligence.
A quantum computing company building the world’s first million qubit, fault-tolerant quantum computer using a silicon photonics approach.
Biotech developing epigenetic reprogramming medicines to restore youthful cell function and extend health span.
Maritime defense technology company developing autonomous surface vessels for next-generation security.
Replit is an AI-powered, browser-based platform that lets anyone build and deploy full applications from natural-language prompts.
Flagship-backed company building Al “Science Factories” to accelerate scientific discovery at scale.
AI biotech applying neuro-symbolic models and real-world clinical data to discover drugs faster.
Biotech creating patient-specific cancer vaccines using AI and multi-omic analysis for solid tumors.
Building hypersonic aircraft for defence and future global travel, shrinking distance and response time.
Unifying data and Al so organizations can turn all their data into intelligent products.
Unifying data and Al so organizations can turn all their data into intelligent products.
Bringing general-purpose AI into the physical world.
Harnessing renewable energy in the open ocean and delivering it around the world.
20% of our net profits go to our Impact Partners
— by design, not as an afterthought.
20% of our net profits go to our Impact Partners — by design, not as an afterthought.
The cost of repurposing current drugs for rare diseases is less than 1% of the cost of developing a new drug.
Every Cure uses AI to match over 4,000 existing drugs with rare diseases, finding treatments for patients with no other options.
Only about 30% of blood cancer and blood disorder patients find a matching donor within their own family.
The rest depend on a stranger and DKMS connects them, having built a registry of 13 million donors that has delivered more than 135,000 second chances at life.
In the Bronx in 2025, almost 30% of gunshot victims were teenagers.
The Bronx Legends Boxing Academy provides free training for hundreds of kids to keep them safe, build discipline, and help transform the Bronx community.